Stock CGS COGSTATE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Cogstate Limited

Equities

CGS

AU000000CGS8

Market Closed - Australian S.E.
Other stock markets
 01:50:54 2024-05-03 am EDT 		5-day change 1st Jan Change
1.4 AUD +2.19% Intraday chart for Cogstate Limited +5.66% -3.11%
Apr. 01 Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment MT
Feb. 22 Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8% MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 45.8 times its estimated earnings per share for the ongoing year.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
COGSTATE LIMITED Stock Cogstate Limited
-3.11% 153M -
MODERNA, INC. Stock Moderna, Inc.
+24.04% 48.09B
B-
LONZA GROUP AG Stock Lonza Group AG
+46.90% 40.62B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.49% 40.43B
B
CELLTRION, INC. Stock Celltrion, Inc.
-6.95% 28.36B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.62% 24.89B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.83% 19.01B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.91% 12.09B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.16% 11.88B
B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.66% 11.8B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CGS Stock
  4. Ratings Cogstate Limited